NCT06631560 (HepE-Onko-BB) is a NA clinical trial of ELISA testing in Hepatitis E Infection, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

Who is sponsoring NCT06631560?

NCT06631560 is sponsored by Medizinische Hochschule Brandenburg Theodor Fontane.

What drugs are being tested in NCT06631560?

Interventions in NCT06631560: ELISA testing.

What condition does NCT06631560 study?

NCT06631560 studies Hepatitis E Infection, Hepatitis; Epidemic, Oncologic Disorders.

Is NCT06631560 still recruiting?

NCT06631560 is currently completed. Last updated 8 October 2024.

Last reviewed 2024-10-08 · How we verify

NCT06631560: HepE-Onko-BB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepatitis E Virus Infection in Oncological Patients

Completed NA Last updated 8 October 2024

What this trial tests

NA trial testing ELISA testing in Hepatitis E Infection in 197 participants. Completed in 1 October 2024.

Timeline

1 September 2020

Primary endpoint
29 October 2021

1 October 2024

Quick facts

Lead sponsor	Medizinische Hochschule Brandenburg Theodor Fontane
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	197
Start date	1 September 2020
Primary completion	29 October 2021
Estimated completion	1 October 2024
Sites	1 location across Germany

Drugs / interventions tested

ELISA testing

Conditions studied

Hepatitis E Infection — all drugs for Hepatitis E Infection →
Hepatitis; Epidemic — all drugs for Hepatitis; Epidemic →
Oncologic Disorders — all drugs for Oncologic Disorders →

Sponsor

Medizinische Hochschule Brandenburg Theodor Fontane

Who can join

Eligibility, any sex, with Hepatitis E Infection or Hepatitis; Epidemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to investigate the prevalence of hepatitis E infection in oncological patients in a rural region of Germany. Consequently, we conducted prospective testing of blood samples from patients with haematological malignancies for evidence of HEV infection using two distinct anti-HEV IgG and IgM enzyme-linked immunosorbent assays (ELISAs). Serum was taken from each patient before treatment initiation and during treatment follow-up. Primary endpoint was determination of HEV seroprevalence. A healthy cohort was established alongside a cohort of patients who had been hospitalised due to a diagnosis of SARS-CoV-2 infection. In addition, oncological participants completed a questionnaire consisting of eight questions focusing on quantitative aspects, to identify risk factors for HEV infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Low Serological Agreement of Hepatitis E in Immunocompromised Cancer Patients: A Comparative Study of Three Anti-HEV Assays.
Haller IE, Reinwald M, Kah J, Eggert FAM, et al · · 2025 · cited 1× · PMID 40265408 · DOI 10.3390/antib14020027

Verify or expand the search:

Other Medizinische Hochschule Brandenburg Theodor Fontane trials

Trials by the same sponsor.

NCT06902337 — Gender Differences in Gastric Cancer Care and Its Adherence to Guidelines in Germany · active not recruiting
NCT07017153 — Patient Decision Aids for Hypertension: A Pilot Study · NA · completed
NCT06575582 — Digital Navigators for Acceptance and Competence Development with Mental Health Apps · NA · recruiting
NCT03052283 — Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) · recruiting
NCT06959849 — Robot-assisted Surgery for Colorectal Cancer Resection: A Population-based Analysis of Prevalence, Trends and Outcomes · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06631560 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medizinische Hochschule Brandenburg Theodor Fontane
Last refreshed: 8 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing